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Abstract
PknG from Mycobacterium tuberculosis is a Ser/Thr protein kinase that regulates key metabolic
processes within the bacterial cell as well as signaling pathways from the infected host cell. This
multidomain protein has a conserved canonical kinase domain with N- and C-terminal flanking
regions of unclear functional roles. The N-terminus harbors a rubredoxin-like domain (Rbx), a
bacterial protein module characterized by an iron ion coordinated by four cysteine residues.
Disruption of the Rbx-metal binding site by simultaneous mutations of all the key cysteine
residues significantly impairs PknG activity. This encouraged us to evaluate the effect of a nitro-
fatty acid (9- and 10-nitro-octadeca-9-cis-enoic acid; OA-NO2) on PknG activity. Fatty acid
nitroalkenes are electrophilic species produced during inflammation and metabolism that react
with nucleophilic residues of target proteins (i.e., Cys and His), modulating protein function and
subcellular distribution in a reversible manner. Here, we show that OA-NO2 inhibits kinase
activity by covalently adducting PknG remote from the catalytic domain. Mass spectrometry-
based analysis established that cysteines located at Rbx are the specific targets of the nitroalkene.
Cys-nitroalkylation is a Michael addition reaction typically reverted by thiols. However, the
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reversible OA-NO2-mediated nitroalkylation of the kinase results in an irreversible inhibition of
PknG. Cys adduction by OA-NO2 induced iron release from the Rbx domain, revealing a new
strategy for the specific inhibition of PknG. These results affirm the relevance of the Rbx domain
as a target for PknG inhibition and support that electrophilic lipid reactions of Rbx-Cys may
represent a new drug strategy for specific PknG inhibition.
Keywords
PknG; Ser/Thr kinase; Nitrated fatty acids; Nitroalkene; Rubredoxin; Mycobacterium tuberculosis
Introduction
Mycobacterium tuberculosis, the causative agent of tuberculosis, is a major public health
problem that causes more than one million deaths every year (http://www.who.int/tb/
publications/global_report/gtbr12_executivesummary.pdf). Several factors comprise the
efficacy of the available pharmacological treatments, including the emergence of drug-
resistant strains, the lack of new drugs, and the bacilli’s ability to persist inside the host
macrophages by inhibiting phagosome maturation. One of the most promising strategies for
drug discovery in tuberculosis is to interfere with bacterial and host signal transduction
mechanisms [1,2].
Genomic studies of M. tuberculosis reveal the presence of 11 “eukaryotic-like” Ser/Thr
protein kinases [3]. Among them, PknG, gains significance by regulating critical processes
in mycobacterial survival [1,4,5]. Functional roles for PknG include regulation of metabolic
processes and interference of signaling pathways from the infected host cell [4,5]. The
inactivation of the pknG gene decreases cell viability and virulence in animal models, and
suggests a central role in controlling intracellular glutamate/glutamine levels [6]. It was
further demonstrated that PknG participates in the regulation of glutamate metabolism via
the phosphorylation of an endogenous substrate (GarA), with similar functions reported for
PknG in the related actinomycete Corynebacterium glutamicum [5,7]. PknG also is a
virulence factor that mediates M. tuberculosis survival within host cells by preventing
macrophage phagosome-lysosome fusion [4]. In addition, inhibition of PknG activity yields
bacteria more susceptible to intracellular degradation [4]. Due to the critical cellular
processes that it controls, PknG inhibition has emerged as an attractive strategy for drug
discovery. The main challenge is to achieve selectivity for PknG inhibition, since the
catalytic mechanisms and the active Ser/Thr protein kinase fold are conserved from
prokaryotes to eukaryotes.
M. tuberculosis PknG is a multidomain protein. The conserved canonical catalytic kinase
domain is flanked by N- and C-terminal domains having undefined functional roles. The C-
terminal domain of PknG contains a tetratricopeptide repeat motif (TPR), a domain that
participates in protein–protein interactions in both eukaryotic and prokaryotic cells [8]. The
TPR domain influences intermolecular interactions, as defined by the crystal structure of
PknG. Notably, whether and how dimerization is linked to enzyme activity is currently
unknown [8]. The N-terminal sequence preceding the kinase domain contains both
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autophosphorylation sites and a rubredoxin-like domain (Rbx) [5]. This latter domain is
typified by an iron ion coordinated to four conserved cysteine residues that participates in
electron transfer reactions [9,10]. The N-terminal sequence of PknG contains two CXXCG
motifs involved in metal binding in Rbx domains. The crystal structure of a PknG construct
confirmed the presence of a Rbx-like arrangement interacting with the kinase domain
without occluding active site accessibility [8]. The role of the Rbx domain in PknG is still
uncertain. Metal binding site disruption by simultaneous mutations of multiple key cysteine
residues has a remarkable effect on PknG activity [8,11], pointing to a relevant functional or
structural role of Rbx domain. This finding encouraged us to evaluate the effect of an
electrophilic fatty acid nitroalkene on PknG activity.
Electrophilic unsaturated fatty acids are generated by diverse enzymatic and redox-related
mechanisms, yielding signaling mediators that induce anti-inflammatory and
chemotherapeutic responses [12]. In particular, nitration confers unsaturated fatty acids with
an electrophilic reactivity that mediates the reversible nitroalkylation of proteins at
nucleophilic Cys and His residues. This thiol-reversible posttranslational modification
modulates protein function and distribution [13]. The reactivity of these molecules is
directed by the electrophilic carbon β to the electron-withdrawing NO2 group, allowing
reversible Michael addition [12–14]. Compared with other electrophilic lipids, nitro-fatty
acids (NO2-FA) reversibly react with thiols at a greater rate constant [12,13,15].
Herein unique structural features of PknG are exploited to inhibit kinase activity by
modification of its non-catalytic Rbx domain. These results reveal a novel mechanism for
inducing kinase inhibition by iron release from the Rbx domain on covalent cysteine
modification by nitrated fatty acids.
Materials and methods
Materials and chemicals
9-Octadecenoic acid (oleic acid; OA) was purchased from Nu-Check Prep (Elysian, MN). 9-
and 10-nitro-octadeca-9-cis-enoic acid (OA-NO2) were prepared as previously described
[16]. GSH, DTT, bathophenanthrolinedisulfonic acid disodium salt (BPS), iodoacetamide
(IAM), and 8-anilino-1-naphthalenesulfonic acid ammonium salt (ANS) were from Sigma
(St. Louis, MO). C18-Omix Pipette tips for sample preparation were from Varian (Lake
Forest, CA). Sequencing grade modified trypsin was from Promega (Madison, WI).
Protein production and purification
Full-length PknG was overexpressed in Escherichia coli BL21 (DE3) cells grown for 24 h at
30 °C without IPTG and supplemented with 100 μM FeCl3. PknG was purified as described
before [5].
Site-directed mutagenesis of PknG was performed by PCR on pET-28a-Δ74PknG using a
QuikChange II site-directed mutagenesis kit (Agilent Technologies). The sequence of the
construct (PknG 74-406, Δ74/TPR) was verified by DNA sequencing. PknG Δ74/TPR was
overexpressed in E. coli BL21(DE3) cells grown at 30 °C until OD600 =0.6, and then ON at
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14 °C after addition of 1 mM IPTG. PknGΔ74/TPR purification was performed as
previously described [5].
GarA (Rv1827) expression was performed in E. coli BL21(AI). Cells were grown in LB
medium supplemented with 0.1% glucose and 10 μg/μL tetracycline at 37 °C until OD600
=0.6, and then for 18 h at 22 °C after addition of 1 mM IPTG and 0.02% arabinose. The
cells were harvested by centrifugation and resuspended in buffer A (5 mM NaH2PO4, 50
mM Na2HPO4, 500 mM NaCl, 5% glycerol, 25 mM imidazole, pH 8.0) supplemented with
Complete protease inhibitor cocktail (Roche). GarA was first purified by metal-affinity
chromatography on a HisTrap Ni2+-IMAC column (GE Healthcare) equilibrated in buffer A,
using a linear imidazole gradient (20–400 mM). The GarA-containing fractions were
dialyzed against buffer B (25 mM Tris-HCl, 150 mM NaCl, 5% glycerol, 1 mM DTT, pH
7.6), and the His6 tag was removed by incubation for 24 h at 18 °C in the presence of His6-
tagged TEV endoprotease at a 1:30 ratio followed by separation on Ni-NTA agarose column
(Qiagen). The untagged GarA was then further purified by size-exclusion chromatography
on a Superdex 75 26/60 column (GE Healthcare) equilibrated in buffer B without DTT.
Protein kinase assay
Protein phosphorylation reactions were performed in 50 mM Hepes buffer, pH 7.0,
containing 2 mM MnCl2 and 100 μM ATP. Activity of PknG was assayed using
recombinant GarA as substrate. The molar ratio of kinase:substrate ranged from 1:10 to
1:20. Reaction mixtures were incubated 30 min at 37 °C and substrate phosphorylation was
evaluated by MALDI-TOF MS. The autophosphorylation activity of PknG was assessed by
incubation of the enzyme in the presence of 2 mM MnCl2 and 100 μM ATP for 40 min at 37
°C. The samples were then digested with trypsin and phosphopeptides were detected by MS.
The effect of OA-NO2-PknG preincubation times on kinase inhibition was assayed. PknG
and OA-NO2 were incubated and at different time points aliquots of treated and control
enzymes were removed for kinase activity determination. Activity assay was performed
using Kinase Glo® Plus Luminescent Kinase Assay (Promega) according to the
manufacturer guidelines. Briefly, activity was tested using GarA as substrate
(kinase:substrate ratio was 1:25) and remaining ATP was quantified by luminescence after
30 min incubation time at 37 °C. For each time point the inhibition relative to control
enzyme is plotted.
MS analysis
Proteolytic digestion was carried out by incubating the proteins with trypsin in 70 mM
ammonium bicarbonate, pH 8.0, for 12 h at 37 °C (enzyme–substrate ratio 1:10). Mass
spectra of peptides mixtures were acquired in a 4800 MALDI TOF/TOF instrument
(Applied Biosystems) in positive ion reflector or linear mode using a matrix solution of α-
cyano-4-hydroxycinnamic acid in 0.2% trifluoroacetic acid in acetonitrile-H2O (50%, v/v)
and were externally calibrated using a mixture of standard peptides (Applied Biosystems).
The molecular mass of the native and phosphorylated GarA was determined using a
sinapinic acid matrix (10 mg/mL in acetonitrile-H2O 50%, 0.2% trifluoroacetic acid).
Alternatively, a linear ion trap mass spectrometer (LTQ Velos, Thermo) coupled on line
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with a nano-liquid chromatography system (easy-nLC, Proxeon-Thermo) was used for
peptide mixtures analysis. Peptides were separated on a reversed-phase column (EASY-
column™ 100 mm, ID 75 μm, 3 μm, C18-A2 from Proxeon) and eluted with a linear gradient
of acetonitrile 0.1% formic acid (0–60% in 60 min) at a flow rate of 400 nL/min.
Electrospray voltage was 1.40 kV and capillary temperature was 200 °C. Peptides were
detected in the positive ion mode using a mass range of 300–2000 in the data-dependent
triple play MS2 mode (full scan followed by zoom scan and MS/MS of the top 5 peaks in
each segment).
Exposure of PknG to OA-NO2 and other Cys-alkylating reagents
Native PknG (ranging from 5 to 10 μM) in 70 mM ammonium bicarbonate, pH 8.0, was
incubated for 10 min at 25 °C with OA-NO2 (0–100 μM) or IAM (0–500 μM) and kinase
activity was immediately measured. PknG treatment with OA-NO2 was also performed in 50
mM sodium bicarbonate, pH 7.2, or 50 mM Hepes buffer, pH 7.3. As a control, PknG was
exposed to OA-NO2 vehicle (methanol) under the same conditions. In addition for OA-NO2
experiments, kinase activity in the presence of equivalent concentration of OA was
determined. In some experiments, after nitroalkene treatment PknG was incubated with DTT
(42 mM) or GSH (24 mM) for 10 min at 25 °C and enzymatic activity was redetermined.
The activity of control PknG in the presence and absence of the thiol containing reagents
was also assayed. Previous to enzymatic digestions, excess of DTT was removed by
immobilization of PknG on reverse-phase Poros 10 R2 beads (Applied Biosystems).
PknG tryptic peptides were isolated by reverse-phase HPLC (Vydac® C18; 2.1 × 100 mm)
and fractions including cysteine-containing peptides were selected after mass analysis by
MALDI-TOF. Selected fractions were dried, resuspended in 70 mM ammonium
bicarbonate, pH 8.0, and treated with OA-NO2 (1:4) for 10 min at 25 °C. Peptide
modification was analyzed by MALDI MS and ESI MS.
The experiments using rabbit muscle GAPDH as model protein were carried out as
previously reported [13].
Iron determination
Control and OA-NO2-treated PknG were loaded onto OMIX C4 pipette tips (Agilent
Technologies) and flow through was collected. Non-bound fraction was incubated for 15
min at 25 °C with 40 mM DTT and iron was determined spectrophotometrically using BPS
as previously described [17].
ANS fluorescence
Concentration of ANS was determined using the molar extinction coefficient ε=5000 M−1
cm−1 at 350 nm [18]. PknG exposed to OA-NO2 under the same experimental conditions
stated above was diluted at 1 μM, dialyzed to remove excess OA-NO2, and incubated with
16 μM ANS. As controls, PknG natively folded and thermally denatured was incubated with
ANS. Fluorescence was collected on a Cary Eclipse fluorescence spectrophotometer
(Varian, Inc.) with the excitation wavelength set on 350 nm and emission between 370 and
650 nm.
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Circular dichroism (far-UV) spectroscopy
Far-UV circular dichroism spectra were performed on OA-NO2-treated and OA-treated
PknG. CD spectra were recorded between 190 and 260 nm on an Aviv 215
spectropolarimeter (Aviv Biomedical), using a cylindrical cell with a 0.02 cm path length
and an averaging time of 1 s per step, with protein samples at 0.5 mg/mL in 25 mM Tris-
HCl, 100 mM NaCl, glycerol 5%, pH 8.0. Five consecutive scans from each sample were
merged to produce an averaged spectrum and corrected using buffer baselines measured
under the same conditions. Data were normalized to the molar peptide bond concentration
and path length and expressed as mean residue ellipticity ([θ] degree · cm2 · dmol−1).
Bioinformatics procedures
Protein sequence homologs to PknG were searched at NCBI’s NR database using CS-Blast
[19], Psi-Blast [20], and HHsenser [21]. All searches were run performing both gapped and
ungapped alignments, in order to selectively detect proteins carrying both Rbx and Ser/Thr
protein kinase domains. Significant hits (Blast E values < 1e−10) found with all methods
with sequence coverage > 75% were kept. Multiple sequence alignments (MSAs) were
computed with Mafft [22], T-Coffee [23], and Prank [24]. Such MSAs were manually
analyzed in order to detect sequences with N-terminal Rbx motifs (all had the kinase
domain). Distance-based phylograms for a subset of 652 sequences (lengths between 500
and 800 amino acids, pairwise identities <76%) were computed with BioNJ [25]. For
proteins with the Rbx domain, maximum-likelihood phylogenetic trees were built by way of
PhyML [26].
Results
PknG inhibition by OA-NO2
To evaluate whether the electrophilic OA-NO2 has an effect on PknG kinase activity, the
enzyme was treated with different concentrations of OA-NO2 (below its critical micelle
concentration) and activity was measured using a recombinant protein substrate, GarA.
Native and phosphorylated GarA were detected by MALDI-TOF MS as ions of m/z 17145
and m/z 17222, respectively [27]. The mass shift corresponds to the incorporation of one
phosphate group (80 Da, Fig. 1A). Kinase activity of PknG exposed to micromolar
concentrations of nitro-oleic acid (molar excess ranging from 1:1 to 1:3) was significantly
inhibited. The ability to phosphorylate GarA was decreased after 10 min incubation of the
kinase with OA-NO2 (50 μM, molar ratio OA-NO2:PknG 5:1) (Fig. 1A). The same extent of
enzyme inhibition was observed when PknG was exposed to OA-NO2 under different
experimental conditions (ammonium bicarbonate, pH 8.0, sodium bicarbonate, pH 7.2, and
Hepes, pH 7.3). As controls, PknG was treated with equivalent concentrations of oleic acid
or methanol (vehicle) and no effect on kinase activity was observed (data not shown).
The effect of OA-NO2 on PknG autophosphorylation was also evaluated to confirm whether
the inhibition observed reflects a general loss of the kinase activity as opposed to a
substrate-specific effect (Fig. 1B). PknG can autophosporylate its N-terminal sequence at
specific Thr residues [5]. The spectrum obtained in the linear mode after tryptic digestion of
native PknG showed unphosphorylated (m/z 5395.8), monophosphorylated (m/z 5475.4), and
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diphosphorylated (m/z 5555.1) ions (sequence 10–60) as previously described (Fig. 1B,
upper panel) [5]. When native PknG was incubated with ATP under phosphorylation
conditions and then digested, the most intense ion observed corresponded to the
diphosphorylated specie while unphosphorylated and monophosphorylated ions were almost
undetectable (Fig. 1B, middle panel). On the other hand, OA-NO2 (30 μM) impairs the
conversion of the un- and monophosphorylated forms of the kinase into the fully
phosphorylated species, indicating that autocatalytic activity is also inhibited by OA-NO2
(Fig. 1B, lower panel).
The effect of OA-NO2 on kinase activity was tested using inhibitor concentrations ranging
from 0 to 80 μM. There was a dose-dependent inactivation of PknG on preincubation of the
enzyme with different OA-NO2 concentrations for 10 min (Fig. 1C). Under these conditions,
50% of enzyme inhibition was reached with 35 μM OA-NO2.
To further characterize the effect of OA-NO2 on PknG, the time course of enzyme inhibition
was studied. PknG and OA-NO2 (or vehicle control) were mixed for time periods ranging
from 0 to 30 min, and kinase activity was then measured using a commercial luminescent
kinase assay (Kinase Glo®). Under these conditions the control activity varies less than 10%
during the 30 min incubation time. The percentage of remaining kinase activity was
calculated with respect to control activity for the same time point. The exposure of PknG to
OA-NO2 decreased kinase activity in a time-dependent manner (Fig. 1D). The dependence
of PknG inhibition on enzyme-OA-NO2 reaction times suggests that the effect of OA-NO2
is mediated by a covalent modification of PknG.
Cysteines in the Rbx domain are the molecular targets of OA-NO2
In order to identify the PknG residues that account for the inhibition of the kinase, samples
obtained by treatment with OA-NO2 under different experimental conditions were digested
with trypsin and peptide mixtures were analyzed by MS (Fig. 2). MALDI-TOF mass spectra
of OA-NO2-treated samples (OA-NO2 concentration up to 35 μM) showed loss of only two
peptides, each one containing a different CXXCG motif of the Rbx domain: m/z 1292.56
and 3530.62 (considering the intramolecular disulfide bond) (Figs. 2A and B). No other
peptide showed a significant change in signal intensity compared with control spectra (data
not shown). These observations were confirmed under all experimental conditions used
(ammonium bicarbonate, pH 8.0, sodium bicarbonate, pH 7.2 and Hepes, pH 7.3).
The expected mass shift for the incorporation of a molecule of OA-NO2 is 327 Da [13].
However, under this experimental conditions no peptide was detected with this mass
increment. Analysis of MALDI-TOF/TOF mass spectra of OA-NO2-treated samples showed
the systematic appearance of a cluster of peaks with 198, 200, and 202 Da greater masses
than the CXXCG-containing peptides (Fig. 2B, upper and middle panel, inset). MS/MS
spectra of the observed ions (m/z 1492.54 and 3730.59) confirmed that these ions
corresponded to modified peptides containing the sequences 105–115 and 122–154,
respectively. Fig. 2C shows the MS/MS spectra of the precursor ion corresponding to the
modified sequence 122–154 (GASEGWC128PYC131GSPYSFLPQLNPGDIVAG-QYEVK)
with a mass increment of 200 Da. The presence of native y-ion series up to y23 together
with the detection of the modified y27 (+200 Da) indicates that any of the residues in
Gil et al. Page 7






















between (i.e., 128CPYC131) might be modified by OA-NO2 (Fig. 2C). Based on the presence
of small signals corresponding to unmodified y24, y24+200 Da, unmodified y26, and
y26+200 Da we postulate that ion m/z=3730.59 is actually a mixture of singly modified
peptides where C128 or C131 have been individually modified by OA-NO2 (Table S1).
Similarly, MS/MS analysis of the other modified Rbx peptide (m/z 1492.54) showed that
only daughter ions that contain the CWNC residues appeared with a modified mass (data not
shown). Although there was not enough sequence information to identify the modified
residue(s) within this motif, based on the previously reported reactivity of the nitrated fatty
acid toward nucleophilic residues these results support that the Cys residues of those
peptides are the main target of OA-NO2 [13].
To further characterize this modification and the observed atypical mass shift, all three
PknG native tryptic peptides that contained Cys residues (m/z 1292.57, m/z 1813.92, and m/z
3530.60) were isolated by RP-HPLC and then treated with OA-NO2. The peptide with the
sequence 155–171 (m/z 1813.92) is the only tryptic peptide of PknG that contains a single
Cys. The modification pattern previously observed was found for all those three Cys-
containing peptides treated with OA-NO2 (Fig. 3). The mass shift for the peptide containing
a single Cys was 196/198/200 Da. This observation is in agreement with the observed mass
shift of 198/200/202 Da for the CXXCG containing peptide, with respect to the native
peptide with an intramolecular disulfide bond. These results indicate that the presence of a
single Cys residue is enough to generate the observed mass shift in MALDI-TOF MS
analyses. In contrast, the analysis of those same peptides by electrospray ionization-MS
showed the expected mass increment of 327 Da, but not the 198/200/202 Da pattern (Figs.
4A and B). MS/MS spectra of the modified peptides unequivocally identified Cys as the
residue modified by OA-NO2 (Figs. 4B and C). In aggregate, these results support the
hypothesis of MALDI ionization-induced decomposition of Cys-nitro-fatty acid adducts.
However, MALDI MS/MS spectra did not provide enough information to interpret the
structure of the modification responsible for the 198/200/202 Da mass shift.
The PknG sequence contains a unique non-rubredoxin Cys (C156). Noticeably, no
consumption of the peptide containing this free Cys was observed on treatment of PknG
with OA-NO2 (Figs. 2A and B, lower panel). In agreement with this observation, no
appearance of a new signal with the previously observed mass shift (198/200/202 Da) or the
theoretical expected mass shift (+327 Da) was observed. To gain further insight into the
reactivity of PknG-Cys residues, iodoacetamide was used to model cysteine alkylation. No
modification of Rbx cysteines was observed for IAM concentrations up to 150 μM (Fig. S1).
Conversely, the unbound Cys156 was alkylated by IAM under similar conditions, revealing a
different reactivity of OA-NO2 vs other alkylating reagents for Cys residues in PknG. When
treating PknG, nitro-fatty acid-modified cysteines tightly bound to the metal ion and
inhibited the enzyme, while treatment with IAM only resulted in modification of free Cys
without affecting kinase activity (Fig. S1). Thus Rbx-Cys, typically reported as non-reactive
with alkylating reagents, is the principal target of reaction with an electrophilic nitroalkene.
At higher concentrations of OA-NO2 (50–80 μM; molar ratio PknG:OA-NO2 from 1:5 to
1:10) the modification of several His residues occurred at very low yields. In agreement with
this observation, there was no significant consumption of His-containing peptides (Fig. S2
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and Table 1). In contrast to cysteine modification, alkylated histidine showed the expected
mass shift of 327 Da when analyzed by MALDI MS and ESI MS. MS/MS analysis of these
peptides confirmed that the incorporation of the nitrated fatty acid occurred at a His residue
(Table 1 and Fig. S2). To confirm that inhibition is a consequence of Cys and not His
modification, studies were repeated using an active PknG construct where N-terminal and
TPR domains were removed (PknGΔ74/TPR). This truncated construct preserves only
His185 out of the seven previously modified His residues. After the exposure of
PknGΔ74/TPR to OA-NO2 the enzyme is fully inhibited, the Cys-containing peptides from
the Rbx domain appeared alkylated and another set of His residues was detected at low
yields (Table S2 and Fig. S3).
Using both enzyme constructs, the Cys-Rbx domain encompasses the only OA-NO2-
modified residues using concentrations up to 35 μM that can render detectable loss of PknG
activity. Altogether, these data indicate that Cys residues at the Rbx domain are the targets
of OA-NO2 and account for enzyme inhibition.
Irreversible PknG inhibition by the reversible OA-NO2-mediated nitroalkylation of the
kinase
We have previously reported that nitrated fatty acids inhibit GAPDH activity by
modification of nucleophilic amino acid residues in a thiol-reversible manner [13]. Herein,
the reversibility of PknG nitroalkylation was analyzed. Treatment of nitroalkylated PknG
with DTT (42 mM) or GSH (24 mM) did not restore kinase activity (Fig. 5A). Under the
same conditions GAPDH activity, used as a control, was restored (Fig. 5A). PknG control
activity was measured in the presence of the thiol-containing reagents. Neither DTT nor
GSH have an effect per se on kinase activity under these experimental conditions.
To evaluate the reversibility of the modification of His and Cys residues in PknG, OA-NO2-
treated samples were exposed to DTT and GSH before protein digestion and MS analysis.
The peptide containing two Rbx-Cys residues (sequence 122–154) showed no change in
mass after nitroalkylation and DTT treatment, supporting reversibility of this reaction of
OA-NO2. In addition, native cysteine-containing peptides were fully recovered after
treatment with DTT (Fig. 5B). Moreover, there were no detectable Cys- or His-nitrated fatty
acid adducts after treatment with DTT or GSH (data not shown). Although nitroalkylation
was reversible as expected, the effect of OA-NO2 on PknG activity was irreversible (Fig.
5A). These results indicate that OA-NO2 is inactivating PknG by an unusual mechanism
involving an irreversible change in PknG structure or function that persists after Cys
nitroalkylation is reversed.
OA-NO2 induces iron release from the Rbx domain
The rubredoxin domain contains an iron ion coordinated by the sulfur atoms of four
conserved cysteine residues, forming an almost regular tetrahedron where Fe3+ is typically
very stable [28,29]. To evaluate the effect of Cys nitroalkylation on the metal center of the
Rbx domain, the amount of iron released on OA-NO2 treatment was measured using a
specific ligand that allows for spectrophotometric determinations. Non-protein-bound iron
present in control and OA-NO2-treated PknG samples was recovered, reduced with DTT,
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and quantified spectrophotometrically. The results showed that PknG nitroalkylation led to
iron release from the Rbx domain (Fig. 6). These data showed that 70% of the iron present
in the Rbx domain was released after protein exposure to 50 μM OA-NO2. As a positive
control, total iron in native protein was determined after Rbx domain disruption by protein
digestion (data not shown).
PknG inhibition by OA-NO2 is not the consequence of a global change in PknG structure
In order to address if the effect of OA-NO2 could be mediated by an unspecific global
distortion of protein tridimensional structure as a consequence of the introduction of a quite
large hydrophobic molecule, global changes in protein structure were analyzed by different
approaches. Enzyme was first treated with OA-NO2 and then ANS, a fluorescent probe that
binds to hydrophobic patches on proteins with a concomitant change in emission spectrum
(Fig. 7A). The same spectra were obtained with native and OA-NO2-modified PknG,
supporting that the hydrophobic surfaces of the protein were not affected by nitroalkylation
(Fig. 7A). This suggests that the enzyme inhibition was not due to large protein structural
changes. In order to discard minor changes in secondary structure circular dichroism
experiments were performed on PknG treated with OA-NO2 or OA (Fig. 7B). The
comparison of the spectra showed no difference between both samples. Overall, these results
suggest that PknG inhibition by OA-NO2 is not due to a general structural modification as a
result of Cys nitroalkylation and iron release from the Rbx domain.
Rbx and kinase domain co-occurrence is restricted to few Actinomycetales
The specificity of OA-NO2 reaction with Cys residues in the Rbx domain of PknG raised the
possibility of a selective inhibition of certain kinases containing this domain. A
bioinformatics analysis informed about the co-occurrence of Rbx and kinase domains.
Multiple sequence alignments of PknG orthologs showed a minority of PknG-like kinases
harboring the CXXCG motif linked to Rbx domains (Fig. 8). In a subset of 652 PknG-like
kinases, the Rbx domain was present in less than 10% (shown in red in Fig. 8). The same
trend was observed in more thorough data sets; e.g., from 1294 proteins, just 88 had the N-
terminal motif. The co-occurrence of Rbx and kinase domains in different species was also
analyzed. Fig. 8 displays a maximum-likelihood phylogenetic tree for a set of 52 sequences
with sequence identities below 90% and above 30%. At sequence identity levels above 25%,
all but two PknG homologs carrying both domains were confined to few suborders of the
Actinomycetales. The two exceptions were Acetivibrio cellulolyticus (Firmicutes) and
Ktedonobacter racemifer (Chloroflexi).
Conservation of the catalytic domain, as well as variability of the N-terminus, has been
described for a number of PknGs [30,31]. However, the presence or absence of the Rbx
domain and sequence conservation levels had not been analyzed. Notably, (a) the joint
occurrence of kinase and Rbx domains is restricted to bacteria from the Actynomycetales
order, including pathogenic and nonpathogenic mycobacteria and (b) the sequences
indicated by a dot in Fig. 8 correspond to different species of Corynebacterium lacking the
CXXCG motifs of the Rbx domain.
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The analysis of the M. tuberculosis genome sequence predicted the presence of 11
eukaryotic-like Ser/Thr protein kinases denoted as pknA to pknL [3]. The importance of
these enzymes in myco-bacterial physiology and virulence has only recently been
appreciated [1,32]. In particular, one of these enzymes, PknG, regulates critical processes in
M. tuberculosis. Previous data support that PknG regulates glutamate metabolism in M.
tuberculosis through the phosphorylation of GarA, an intermediate regulator of three
metabolic enzymes [5,33]. PknG is also an important virulence factor that inhibits
phagosome maturation in infected macrophages through an unknown mechanism [4,11]. In
agreement with this, inhibition of PknG activity yields bacteria more susceptible to
macrophage killing.
In this scenario, PknG inhibitors represent a promising drug development strategy, with a
few PknG inhibitors of moderate activity previously described [2,8,34]. These inhibitors are
directed toward the kinase catalytic site. For example, AX20017 displays some degree of
specificity toward PknG, based on structural features of its active site [8]. It is already
appreciated that active “eukaryotic-like” kinase folding is highly conserved even among
different kingdoms [35], making inhibitor specificity problematic. An alternative strategy
for selective kinase inhibition is to target other protein domains besides active site. Herein,
we report that the inhibition of PknG kinase activity by OA-NO2 occurs by reversible
alkylation of specific Cys residues of the Rbx domain, outside the catalytic domain.
The combination of Rbx and kinase domains has not been described for any other proteins
than PknG-like kinases. PknG orthologs are present in all mycobacterial genomes sequenced
to date, as well as in other related actinomycetes [31]. While the kinase domain is very well
preserved, some other domains are not. In particular, the N-terminal Rbx domain appears in
few PknG-like kinases from Actinomycetales (Fig. 8). Moreover, PknG ortholog from
Corynebacterium spp, with the equivalent function toward glutamate metabolism, lacks the
Rbx domain. This highlights the relevance of nitrated fatty acids as potential selective
inhibitors acting on a subset of Rbx-containing PknG-like enzymes among prokaryotic and
eukaryotic kinases.
The reported structure of a truncated form of PknG shows that the rubredoxin-like domain is
closely associated with the N-terminal lobe of the catalytic domain of PknG, facing the
kinase active site (Scheme 1). Thus, the modification of the Rbx domain could directly
affect the active kinase conformation. Herein, the modification of Rbx-Cys by a nitroalkene
was reversible and leads to a permanent effect on enzyme activity because of concomitant
loss of an iron atom. Nitroalkylation of PknG did not induce a global change in structure
(Fig. 7). In support of this, the conversion of bacterial rubredoxins to the apo form is
followed by only minor structural changes [28], suggesting that minor local structural
changes and/or the loss of iron could be mediating a regulatory role of kinase activity. To
confirm the effect of iron loss on kinase activity, we attempted to reincorporate the iron ion
into OA-NO2-treated PknG. Nevertheless, we were not able to reassemble the Rbx domain
by OA-NO2 removal by thiol reagents in the presence of iron salts. In addition, previous
attempts to generate apo-Rbx-PknG under nondenaturating conditions failed, and thus did
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not permit more definitive conclusions. Elucidating the effect of iron release on more
detailed Rbx structure and function will require further investigation. Significantly, PknG is
one of the two soluble kinases present in M. tuberculosis lacking an extracellular sensor
domain. The signals that activate/inactivate PknG and the mechanism for activity regulation
are still unknown.
Fatty acid nitroalkenes are electrophilic species produced during inflammation and
metabolism that react with nucleophilic amino acid residues of target proteins (i.e., Cys and
His residues), reversibly modulating protein function and subcellular distribution.
Nitroalkene reactivity is dictated by the electrophilic character of the β-carbon proximal to
the alkenyl NO2 group (Scheme 2) [16]. Nitroalkene fatty acids react with nucleophilic
residues via a Michael addition to generate covalent adducts that can be reversed by thiol-
containing molecules. This typically restores the native protein function [13]. Rbx-Cys are
viewed as poor nucleophiles that do not react with low molecular weight alkylating reagents.
However, mass spectrometry-based analysis confirmed that cysteines located at Rbx domain
are the targets for nitroalkene reaction with PknG. While the kinase sequence contains
reactive Cys and His residues, this is a novel reactivity of nitroalkenes with Rbx-Cys,
wherein irreversible inhibition is achieved by reversible nitroalkylation of a redox-sensitive
non-catalytic domain. The molecular basis of the selectivity of this reaction requires
additional investigation.
Xanthine oxidoreductase (XOR) inhibition by OA-NO2 was the first irreversible inhibition
reported for fatty acid nitroalkenes. As in the case of PknG, XOR inhibition was not
reversed by thiol reagents [15]. At that time, we postulated that the inhibition of XOR was
mediated via: (1) an irreversible covalent reaction between OA-NO2 and XOR or (2) a
reaction of the nitroalkene with the dithiolene of the pterin moiety and the concomitant loss
of the molybdenum atom, with no direct evidence supporting either contention [15].
Inhibition of other enzymes by nitro-fatty acids was also previously reported [13,36]. OA-
NO2 inhibition of both GAPDH and PknG is achieved within the same range of micromolar
concentrations. It is important to note that OA-NO2 is considered a potent inhibitor of
GAPDH, a key enzyme of intermediate metabolism that, due to a catalytic Cys residue, has
also been postulated to be a redox sensor. OA-NO2 is almost an order of magnitude more
reactive toward GAPDH than hydrogen peroxide and peroxynitrite [13].
Covalent inhibitors display time-dependent inhibition and their potency must be
characterized by the inactivation rate for different inhibitor concentrations. In the case of
OA-NO2, the determination of an inhibition constant for PknG is difficult for several
reasons. OA-NO2 concentration cannot be readily increased over its critical micelle
concentration and increasing inhibitor concentration also increases the number of
nonspecific covalent modifications, complicating kinetic analysis. There is a remarkable
effect on kinase activity, with micromolar concentrations of OA-NO2 at PknG:OA-NO2
ratios of 1:3 and 1:5. Even though this does not allow us to evaluate inhibition constants, the
data point to a potent effect of OA-NO2 on kinase activity.
Analysis of Cys-alkylated peptides showed an unexpected mass shift by MALDI-TOF/TOF
analysis. We hypothesized that laser ionization induces photodecomposition of cysteine-
Gil et al. Page 12






















OA-NO2 adducts, generating the observed pattern with a mass shift of 198/200/202 Da. In
support of this, decomposition of nitro-compounds during MALDI analysis has been
previously reported [37]. In contrast to cysteine modification, alkylated histidine showed the
expected mass shift of 327 Da, indicating that the mass increment of 198/200/202 Da is a
fingerprint of Cys modification when detected by MALDI MS. This can also explain why
Cys-OA-NO2 adducts were not detected in previous MALDI analyses [13]. MALDI MS/MS
spectra of the modified peptides with this atypical mass increments did not show fragments
of the 198/200/202 Da modification, thus not allowing a structural characterization.
This study exploited the unique structural characteristics of the multidomain protein kinase
PknG for specific inhibition of enzymatic activity, revealing a new mechanism for PknG
inhibition involving the Rbx domain rather than the catalytic domain. Electrophilic fatty
acids thus represent a class of mediators that can induce the specific inhibition of a small
subset of kinases containing a Rbx domain. Many in vivo studies have been performed with
nitro oleic acid and are recently reviewed in Schopfer et al. [38]. This warrants further study
of these PknG inhibitors in more complex model systems.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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OA-NO2 inhibits PknG kinase activity. (A) GarA phosphorylation by PknG. Linear
MALDI-TOF mass spectrum of GarA (m/z 17145, dashed line), GarA phosphorylated by
PknG using a molar ratio PknG:GarA of 1:20 (m/z 17222, gray line), and GarA
phosphorylated by PknG pretreated with 50 μM OA-NO2 for 10 min (m/z 17143, black line).
(B) PknG autophosphorylation. Upper panel: linear MALDI-TOF spectrum of native PknG
after tryptic digestion showing basal autophosphorylation pattern. Unphosphorylated peptide
with seq. 10–60 (m/z 5395.8), monophosphorylated (m/z 5475.4), and diphosphorylated
species (m/z 5555.1) are detected as expected. Middle panel: linear MALDI-TOF spectrum
of PknG after incubation with ATP and Mn2+ and further typtic digestion
(autophoshorylation positive control). Diphosphorylated peptide (m/z 5555.0) is the most
intense ion observed while unphosphorylated and monophosphorylated ions were almost
undetectable. Lower panel: linear MALDI-TOF spectrum of tryptic digestion of PknG
treated with 30 μM OA-NO2 for 10 min before autophosporylation reaction. The detection
of all three forms of the phosphorylatable peptide indicates that OA-NO2 impairs conversion
into the fully phosphorylated species. The spectra are representative of three independent
experiments. (C) Dose-dependent inhibition of PknG by OA-NO2. PknG (8 μM) was
incubated with OA-NO2 ranging from 0 to 80 μM in 70 mM ammonium bicarbonate, pH
8.0, at 25 °C. As a control, PknG was incubated with vehicle under the same experimental
conditions. After 10 min of incubation enzyme activities were determined. Samples were
analyzed in triplicates. (D) Time-dependent inhibition of PknG by OA-NO2. PknG (10 μM)
was incubated with 50 μM OA-NO2 (treated PknG) or vehicle (control PknG) in 70 mM
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ammonium bicarbonate, pH 8.0, at 25 °C. At the indicated time points aliquots of control
and treated PknG were removed, and enzyme inhibition was determined using Kinase Glo®
by comparison with control activity. Samples were analyzed in triplicates.
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Modification sites of PknG by OA-NO2. (A) MALDI-TOF mass spectrum of Cys-
containing peptides generated by tryptic digestion of untreated PknG. Upper panel: peak m/z
1292.56 corresponds to sequence FC106WNC109GRPVGR with an intramolecular
disulphide bridge. Middle panel: peak m/z 3530.62 corresponds to sequence
GASEGWC128PYC131G-SPYSFLPQLNPGDIVAGQYEVK with an intra molecular
disulphide bridge. Lower panel: peak m/z 1813.92 (GC156IAHGGLGWIYLALDR) is
indicated. (B) MALDI-TOF mass spectrum of Cys-containing peptides generated by tryptic
digestion of OA-NO2-treated PknG. Upper panel: peak m/z 1292.57 is partially consumed
and a new peak appears showing a mass increment of 198/200/202 Da. Inset: zoom in
showing the 198/200/202 pattern and isotopic distribution. Middle panel: peak m/z 3530.61
is also partially consumed and again a new signal appears showing a mass increment of
198/200/202 Da. Inset: zoom in showing the 198/200/202 mass increment pattern. Lower
panel: signal intensity of m/z 1813.93 is unchanged on treatment with OA-NO2, and in
agreement with this observation there were no new signals in this m/z range (the arrows
indicate the expected m/z values: +327 for OA-NO2 modification and +198/200/202 for the
previously experimentally observed mass shift). (C) MALDI-TOF MS/MS spectrum of ion
at m/z 3730.60 obtained from tryptic digestion of OA-NO2-treated PknG. Sequence 122–154
showing main observed fragments (natives or modified). The spectra are representative of
five independent experiments.
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Treatment of isolated Cys-containing peptides from PknG with OA-NO2. (A) MALDI-TOF
mass spectrum of peptides generated by tryptic digestion of native PknG. Peptides were
purified by reverse-phase chromatography prior to MS analysis. Upper panel: peak m/z
1294.63 (FC106WNC109GRPVGR); middle panel: peak m/z 1815.04
(GC156IAHGGLGWIYLALDR); and lower panel: peak m/z 3532.80
(GASEGWC128PYC131GSPYSFLPQLNPGDIVAGQYEVK). The reduced peptides
containing the CXXCG sequence are detected after the chromatographic step but are
spontaneously converted into the intermolecular disulphide bridged oxidized form. (B)
MALDI-TOF mass spectrum of peptides isolated in (A), treated with OA-NO2. Upper panel:
a new peak appears showing a mass shift of 198/200/202 Da relative to m/z 1292.63; middle
panel: a new peak appears showing a mass shift of 196/198/200 Da relative to m/z 1814.94;
and lower panel: a new peak appears showing a mass shift of 198/200/202 Da relative to m/z
3530.61.
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MS/MS spectra of OA-NO2 modified peptide 155–171. (A) MALDI ionization. MS/MS
spectrum of ion at m/z 2014.31 (native peptide +200 Da) obtained using MALDI-TOF MS.
(B) ESI ionization. MS/MS spectrum of ion at m/z 2141.85 (native peptide +327 Da)
obtained using LC-MS. (C) List of theoretical m/z values of fragment ions from peptide of
m/z 2141.85 (GC156IAHGGLGWIYLALDR modified by OA-NO2). y- and b-ions detected
by LC-MS are highlighted in bold.
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Irreversible PknG inhibition by reversible OA-NO2-mediated nitroalkylation. (A) PknG was
inhibited by incubation with OA-NO2 (50 μM) in 70 mM ammonium bicarbonate, pH 8.0, at
25 °C for 10 min, as previously described. Kinase activity of PknG inhibited by OA-NO2
was measured (PknG+OA-NO2). Subsequently, nitroalkylated samples were treated with
DTT (42 mM) or GSH (24 mM) for 15 min at 25 °C and kinase activity was remeasured
(PknG+OA-NO2+RSH). Activity recovery was expressed as a ratio between [activity of
PknG+OA-NO2+RSH]/[activity PknG+OA-NO2] where 1 means no activity recovery after
thiol-containing agent treatment. GAPDH was used as a positive control: after DTT
treatment 90% of the initial activity was recovered representing a 12-fold increase in the
enzyme activity after the RSH treatment. Treatment of control PknG samples with 42 mM
DTT or 24 mM GSH showed that these concentrations of the thiol reagents had no effect on
kinase activity per se. Three independent experiments were performed. (B) MALDI-TOF
mass spectrum of peptides generated by tryptic digestion of PknG. Upper panel: untreated
PknG; middle panel: PknG exposed to OA-NO2; and lower panel: idem middle panel+42
mM DTT. In each panel the native or nitroalkylated form of the peptide with the sequence
122–154 that includes the Rbx-Cys 128 and 131 is shown. All the spectra are representative
of three independent experiments.
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OA-NO2 induces iron release from Rbx domain. Non-protein-bound iron present in control
and OA-NO2-treated PknG samples was recovered, reduced with DTT, and quantified as
Fe2+ using bathophenantrolinedisulfonic acid. The complex absorbs at 535 nm (ε535 nm
[BPS · Fe2+]=22140 M−1 cm−1 [17]). Iron present on native PknG samples (dashed line) or
from OA-NO2-treated PknG (solid line) is shown.
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OA-NO2 modification does not generate a global change in PknG structure. (A)
Fluorescence of PknG-ANS complexes was collected using excitation wavelength set on
350 nm and emission between 370 and 650 nm. PknG natively folded is represented as solid
black line; PknG exposed to OA-NO2 is shown as solid gray line; and PknG thermally
denatured is indicated as dashed black line. (B) Far UV-CD spectra of OA-NO2-treated
PknG (black circles) and OA-treated PknG (white diamonds).
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Rbx and kinase domain co-occurrence is restricted to few Actinomycetales. Left: Distance-
based tree of 652 sequence homologs with pairwise identities <76%. The sequences were
aligned with Mafft [22] and the tree was built with BioNJ [39]. Zoom in the clade containing
sequences harboring both kinase and Rbx domains. They were multiply aligned using T-
Coffee [23] for a maximum-likelihood reconstruction with PhyML [26]. The two non
actynobacterial sequences (A. cellulolyticus and K. racemifer) were omitted. Right:
Maximum-likelihood phylogenetic reconstruction for a set of 52 dissimilar homologous
proteins. Species names and accession numbers are shown. Branch support values are shown
in red, omitting a number of internal nodes for clarity. Scale bar indicates average
substitutions per site.
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Overall fold of PknG kinase and rubredoxin domains. The catalytic domain of M.
tuberculosis PknG (PDB code 2PZI) shown in ribbon representation (colored from blue to
red) interacts with the Rbx domain (ribbon+surface representation). The four Cys residues of
the Rbx domain and the bound metal (red) are shown. The figure was drawn with Pymol.
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Nitrated oleic acid (OA-NO2). Two regioisomers of OA-NO2 were synthesized by
nitrosenylation of oleic acid yielding 9- and 10-nitro-9-cis-octade-cenoic acids. Taken from
[16].
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Table 1
Identification of OA-NO2-modified residues in PknG.
OA-NO2:PknG ratioa
Low High
Peptide from-to Modified residue Assigned sequenceb (observed m/z)
Peptides containing modified cysteine residues (Δm=198/200/202Da)
105–111 C106 or C109 FCWNCGR (1081.31/1083.30/1085.33) x x
105–115 C106 or C109 FCWNCGRPVGR (1490.51/1492.54/1496.55) x x
122–154 C128 or C131 GASEGWCPYCGSPYSFLPQLNPGDIVAGQYEVK
(3728.55/3730.59/3732.60)
Peptides containing modified histidine residues (Δm=327 Da)
x x
182–199 H185 GLVHSGDAEAQAMAMAER (2171.09) x
420–443 H430 or H440 STFGVDLLVAHTDVYLDGQVHAEK (2941.56) x
488–510 H488 HGALDADGVDFSESVELPLMEVR (2813.41) x
558–573 H558 HFTEVLDTFPGELAPK (2128.15) x
635–640 H635 HFTTAR (1059.61) x
698–714 H702 or H711 ASTNHILGFPFTSHGLR (2182.21) x
733–743 H733 HRYTLVDMANK (1674.91) x
a
Low OA-NO2:PknG ratio means a molar ratio in between 1:1 and 3:1 ([OA-NO2] between 8 and 30 μM). High OA-NO2:PknG ratio means a
molar ratio 10:1 ([OA-NO2] =80 μM).
b
The sequence and alkylation sites were confirmed by MS/MS analysis.
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